Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Aug 16, 2024

BUY
$1.25 - $2.51 $875 - $1,756
700 New
700 $0
Q1 2023

May 15, 2023

SELL
$2.66 - $4.36 $10,424 - $17,086
-3,919 Reduced 84.85%
700 $1,000
Q4 2022

Feb 14, 2023

SELL
$2.81 - $39.7 $11,408 - $161,182
-4,060 Reduced 46.78%
4,619 $14,000
Q3 2022

Nov 14, 2022

BUY
$3.97 - $42.7 $29,294 - $315,083
7,379 Added 567.62%
8,679 $32,000
Q2 2022

Oct 27, 2022

SELL
$5.93 - $15.61 $296 - $780
-50 Reduced 3.7%
1,300 $8,000
Q2 2022

Aug 15, 2022

SELL
$5.93 - $15.61 $296 - $780
-50 Reduced 3.7%
1,300 $8,000
Q1 2022

Oct 27, 2022

BUY
$5.06 - $13.8 $252 - $690
50 Added 3.85%
1,350 $19,000
Q1 2022

May 13, 2022

BUY
$5.06 - $13.8 $2,023 - $5,520
400 Added 42.11%
1,350 $19,000
Q4 2021

Feb 14, 2022

BUY
$2.92 - $42.3 $2,190 - $31,724
750 Added 375.0%
950 $11,000
Q3 2021

Nov 15, 2021

BUY
$3.4 - $8.3 $680 - $1,660
200 New
200 $1,000

Others Institutions Holding LGVN

About Longeveron Inc.


  • Ticker LGVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,925,940
  • Market Cap $11.2M
  • Description
  • Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...
More about LGVN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.